TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02844842

Intervention type: BIOLOGICAL
Intervention: Allergovac Poliplus

Intervention type: BIOLOGICAL
Intervention: Allergovac Poliplus
Study: NCT02309411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: With age and body-weight adjusted twice daily dosing of rivaroxaban as Oral Suspension to achieve a similar exposure as that observed in adults treated with 20 mg rivaroxaban once daily, and no other anticoagulant
Study: NCT01677702

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yili Lactoferrin ShuHua Milk (Lactoferrin 10mg/100ml)
Description: Total 250mL milk (with lactoferrin 10mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Recombined low protein milk
Description: Total 250ml of placebo milk will be taken once a day at 10am daily during the 84 day intervention.
Study: NCT02387892

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cheese & yogurt + Vitamin D
Description: cheese \& yogurt with added 420 IU cholecalciferol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cheese & yogurt
Description: Cheese \& yogurt without added vitamin D
Study: NCT00259922

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvimopan
Description: 0.5 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alviompan
Description: 0.5 mg BID
Study: NCT03960671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam/diazepam/propofol
Description: Therapeutic drug monitoring of anxiolytics
Study: NCT01109823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous administration of levofloxacin
Description: Intravenous administration of levofloxacin is used.
Study: NCT03060174

Intervention type: OTHER
Group type: OTHER
Intervention: monitoring and non-medical prophylaxis of delirium
Study: NCT01167114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-9090
Description: Given intravenously on Day 1, 8 and 15 of each 4 week cycle.
Study: NCT00177840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Study: NCT02640404

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: 0.5 mL, Intramuscular. 2 doses 3 months apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: 0.5 mL, Intramuscular.
Study: NCT02149758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoricoxib
Study: NCT01946958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in PC Triple P
Description: PC Triple P is a brief parenting intervention combining specific advice from provider with parent rehearsal and self-evaluation.
Study: NCT02986607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parathyroid hormon 1-84
Description: Hypoparathyroidism patients will receive Natpara in continous subcutaneous infusion delivered by a pump for 4-7 days.
Study: NCT02209012

Intervention type: DRUG
Intervention: Aminolevulinic Acid (ALA)
Description: Levulan PDT given in CP0108

Intervention type: DRUG
Intervention: Topical Solution Vehicle
Description: Vehicle PDT given in CP0108

Intervention type: DEVICE
Intervention: BLU-U Blue Light Photodynamic Therapy Illuminator
Description: PDT given in CP0108

Intervention type: DEVICE
Intervention: BLU-U Blue Light Photodynamic Therapy Illuminator
Description: PDT given in CP0108
Study: NCT01960647

Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous transluminal angioplasty with uncoated balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous transluminal angioplasty with Paclitaxel balloon
Study: NCT00499863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate transdermal system
Description: dose optimization of 4 doses of the MTS transdermal patch over the same duration of wear

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patch
Study: NCT01946958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care As Usual
Description: Pediatric residents not exposed to PC Triple P provide their standard care to parents struggling with parenting issues or child behavior concerns.
Study: NCT02666196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAA-I
Study: NCT04299516

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-team simultaneous bilateral total knee arthroplasty
Description: Bilateral total knee arthroplasty can be performed in three different ways: single-stage, two-team simultaneous bilateral total knee arthroplasty; single-stage, one-surgeon, and two-stage bilateral total knee arthroplasty. Two surgeons will operate simultaneously on one side for two-team SBA.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-team simultaneous bilateral total knee arthroplasty
Description: One surgeon will operate sequentially on both sides for one-surgeon SBA
Study: NCT02535364

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCAR015 (CD19-targeted CAR T cells)
Description: Part A: Following leukapheresis and concurrent with generation of JCAR015, participants received, at the Investigator's discretion, cytoreductive chemotherapy based on the Investigator's choice of regimens and/or supportive care.~Part B: Participants who were eligible for treatment in Part B received two IV doses of JCAR015 CAR T cells separated by 14 to 28 days. JCAR015 infusion was preceded by lymphodepleting chemotherapy with cyclophosphamide alone or cyclophosphamide + fludarabine.
Study: NCT01296022

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of subcutaneous ICD
Description: Implantation of subcutaneous ICD

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of transvenous ICD
Description: Implantation of transvenous ICD
Study: NCT04792125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External electrical stimulation (EES) added to pelvic floor muscle training (PFMT)
Description: Patients will be treated with the Innovo device using eight external electrodes with a combined stimulator. Electrodes will be applied to the buttocks, outer hips and anterior and posterior proximal thighs 3 days a week for 30 minutes each session.~While explaining the exercise to the patients, it was stated that 1 set of exercise consisted of 10 fast contractions and 10 slow contractions. For the first 2 weeks, they were asked to exercise 2 sets a day, every day. Thus, in the first 2 weeks, 20 fast contractions and 20 slow contractions were performed. Then, 2 sets were increased every two weeks and the exercise was ended as 8 sets (80 fast and 80 slow contractions) at the end of the 8th week.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: External electrical stimulation
Description: Patients will be treated with the Innovo device using eight external electrodes with a combined stimulator. Electrodes will be applied to the buttocks, outer hips and anterior and posterior proximal thighs 3 days a week for 30 minutes each session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training (PFMT)
Description: While explaining the exercise to the patients, it was stated that 1 set of exercise consisted of 10 fast contractions and 10 slow contractions. For the first 2 weeks, they were asked to exercise 2 sets a day, every day. Thus, in the first 2 weeks, 20 fast contractions and 20 slow contractions were performed. Then, 2 sets were increased every two weeks and the exercise was ended as 8 sets (80 fast and 80 slow contractions) at the end of the 8th week.
Study: NCT02661100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg/kg by IV infusion on Day 1 of each 3 week cycle. Given until disease progression

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDX-1401
Description: 1mg given subcutaneously on day 1 of each 3 week cycle. Given for 4 cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: 2mg given subcutaneously on day 1 and 2 of each 3 week cycle. Given for 4 cycles
Study: NCT02138643

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic surgery
Description: These will be treated with Endoscopic surgery - Peroral endoscopic myotomy (POEM)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laparoscopic surgery
Description: These will be treated with Laparoscopic surgery - Laparoscopic Heller myotomy.
Study: NCT02634788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Buprenorphine sublingual spray delivered via single 100 μL spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Buprenorphine sublingual spray delivered via single 100 μL spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Buprenorphine sublingual spray delivered via single 100 μL spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
Study: NCT02452086

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Level Laser(Ga-As)
Description: Low level laser therapy(904 nm Wavelength), 90 milliwatt, 2 Joule/centimeter2

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: LLLT with zero intensity
Study: NCT02464683

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VitaminD
Description: 200 International Units (oral dose) daily of 60 days
Study: NCT03737786

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tight control of end-tidal CO2 levels
Description: The desired end-tidal PCO2 levels will be achieved by endotracheal intubation and controlled ventilation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tight control of end-tidal CO2 levels
Description: The desired end-tidal PCO2 levels will be achieved by endotracheal intubation and controlled ventilation
Study: NCT02666196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAA-I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAA-I

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03173690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication reconciliation at the ICU
Description: Medication reconciliation performed according to Integrated Medicines Management model

Intervention type: OTHER
Group type: OTHER
Intervention: Medication Reconciliation at the Ward
Description: Medication reconciliation performed according to Integrated Medicines Management model

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Reconciliation at the Ward
Description: Medication reconciliation performed according to Integrated Medicines Management model
Study: NCT03466203

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LLF580
Description: LLF580 300mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to LLF580
Study: NCT01864369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eCounseling + Usual Care
Description: This intervention will use film vignettes and interactive web pages. The e-counseling messages will promote: (i) validation of the subject's stage of readiness for behavior change, (ii) collaborative participation by means of subject-selected menus, (iii) reinforcement of change talk to resolve ambivalence, (iv) use of self-help information and e-tools for self-monitoring of targeted self-care behaviors, and (v) development of cognitive-behavioral skills to build and strengthen efficacy. Messages will be proactively sent to Controls according to the following schedule: weekly for months 1 to 4, bi-weekly for months 5 to 8, and monthly for months 9 to 12.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eCounseling + Usual Care
Description: This intervention will use film vignettes and interactive web pages. The e-counseling messages will promote: (i) validation of the subject's stage of readiness for behavior change, (ii) collaborative participation by means of subject-selected menus, (iii) reinforcement of change talk to resolve ambivalence, (iv) use of self-help information and e-tools for self-monitoring of targeted self-care behaviors, and (v) development of cognitive-behavioral skills to build and strengthen efficacy. Messages will be proactively sent to Controls according to the following schedule: weekly for months 1 to 4, bi-weekly for months 5 to 8, and monthly for months 9 to 12.
Study: NCT00998075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole/ASA Fixed Combination
Description: Capsule, oral, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole - Nexium
Description: Clinical Trial Capsule or MUPS Tablet, oral, single dose
Study: NCT01846000

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low-level laser treatment
Description: A gallium-aluminum-arsenide laser will be employed for the LLLT and placebo treatment. The device will be calibrated with a wavelength of 780 nm, energy density of 25 J/cm2, power of 50 mW and power density of 1.25 W/cm2. Exposure time will be 20 seconds per point, resulting in a total energy of 1 J per point. The spot application method will be used in contact with the skin and with a conventional tip, covering an area of 0.04 cm2.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: low-level laser treatment
Description: A gallium-aluminum-arsenide laser will be employed for the LLLT and placebo treatment. The device will be calibrated with a wavelength of 780 nm, energy density of 25 J/cm2, power of 50 mW and power density of 1.25 W/cm2. Exposure time will be 20 seconds per point, resulting in a total energy of 1 J per point. The spot application method will be used in contact with the skin and with a conventional tip, covering an area of 0.04 cm2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low-level laser treatment
Description: A gallium-aluminum-arsenide laser will be employed for the LLLT and placebo treatment. The device will be calibrated with a wavelength of 780 nm, energy density of 25 J/cm2, power of 50 mW and power density of 1.25 W/cm2. Exposure time will be 20 seconds per point, resulting in a total energy of 1 J per point. The spot application method will be used in contact with the skin and with a conventional tip, covering an area of 0.04 cm2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low-level laser treatment
Description: A gallium-aluminum-arsenide laser will be employed for the LLLT and placebo treatment. The device will be calibrated with a wavelength of 780 nm, energy density of 25 J/cm2, power of 50 mW and power density of 1.25 W/cm2. Exposure time will be 20 seconds per point, resulting in a total energy of 1 J per point. The spot application method will be used in contact with the skin and with a conventional tip, covering an area of 0.04 cm2.
Study: NCT01452646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk-adapted, MRD-directed therapy
Description: The general objective of this study is that of setting up a multicentre, risk-adapted study that relies on pre-treatment cytogenetic/genetic features and post-consolidation assessment of MRD to establish the final risk assignment and treatment of younger (≤ 60 years) patients with AML. Aim of this clinical trial is to verify whether the delivery of a post remission therapy whose intensity is risk-driven will improve the outcome in terms of both increased anti-leukemic efficacy and reduced therapy-related toxicity.
Study: NCT02293746

Intervention type: DEVICE
Group type: OTHER
Intervention: Inspire® Upper Airway Stimulation (UAS) System
Description: This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System is a permanent, implantable therapy device, which consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the patient receives a remove to activate the therapy.
Study: NCT03234153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (Imfinzi)
Description: Durvalumab 1500 mg i.v. every 4 weeks in combination with Tremelimumab 75 mg i.v. every 4 weeks for a total of 4 cycles before surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab 75 mg i.v. in combination with Durvalumab 1500 mg i.v. every 4 weeks every 4 weeks for a total of 4 cycles before surgery.
Study: NCT02223884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel 35mg/m2
Description: D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC3
Description: D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
Study: NCT01965782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [^14C]-LY3023703
Description: Administered orally
Study: NCT03249610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Intervention Trial with Multi-Component Lifestyle Intervention for reduction of body weight and cardio-metabolic risk factors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Intervention Trial with Multi-Component Lifestyle Intervention for reduction of body weight and cardio-metabolic risk factors
Study: NCT00615186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuradiab + Radiotherapy + Temozolomide
Description: Prior Surgery~Rickham Catheter placement 99mTc-DTPA Flow Study~Neuradiab Dosimetry Study~Neuradiab Therapeutic Dose Administration~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + temozolomide (75 mg/m2/day) over 6.5 weeks.~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy + Temozolomide
Description: Prior Surgery: Gross total resection (\< 1 cm. enhancing rim)~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + 42 days of temozolomide (75 mg/m2/day) over 6.5 weeks~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment.
Study: NCT06212908

Intervention type: OTHER
Group type: OTHER
Intervention: Basic Periodontal Therapy
Description: All patients received oral hygiene instructions (interproximal cleaning with floss and interdental brushes, brushing instructions on the Bass technique). The patients were also encouraged to brush the back of the tongue once a day. Subsequently, all patients underwent supragingival scaling, prophylaxis, and polishing. Supragingival scaling was performed using manual instruments (Gracey curettes) and an ultrasonic device.
Study: NCT05163613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: magnetostimulation
Description: Treatment parameters: 12 minutes M2P2 program, with increasing intensity from 1 to 8. The authors applied magnetic field with a frequency of 180 - 190 Hz, pulse packet frequencies between 12.5 and 29 Hz, packet groups 2.8 - 7.6 Hz, series 0.08 - 0.3 Hz, with magnetic induction B= 3.2 µT (on average) and B = 40 µT at a pulse peak.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: Standard therapy used in all patients consisted of the use of pharmacological agents necessary to treat the viral infection (antiviral drugs, antibiotics, dexamethasone) and the inclusion of proper care, education, occupational therapy, self-service learning, breathing exercises and motor mobilization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: Standard therapy used in all patients consisted of the use of pharmacological agents necessary to treat the viral infection (antiviral drugs, antibiotics, dexamethasone) and the inclusion of proper care, education, occupational therapy, self-service learning, breathing exercises and motor mobilization.
Study: NCT01626222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Exemestane according to the individual label. Commercially available Exemestane will be supplied as tablets of 25 mg strength for oral administration. Complete guidelines for management and administration of Exemestane can be found in the package insert. Exemestane will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet of 25 mg Exemestane orally. Package insert instructions should be followed. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Exemestane exactly as prescribed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Description: Everolimus (RAD001) is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Everolimus according to the individual label. Everolimus is formulated as tablets of 10 and 5 mg strength for oral administration. All study medication will be packaged into blister packs. The blisters should be opened only at the time of administration, as the drugs are both hygroscopic and light sensitive. Everolimus will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet × 10 mg Everolimus orally with a large glass of water once daily at the same time each day with or without food. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Everolimus exactly as prescribed.